Опубликована: Янв. 1, 2024
Язык: Английский
Опубликована: Янв. 1, 2024
Язык: Английский
Journal of Molecular Biology, Год журнала: 2025, Номер unknown, С. 169008 - 169008
Опубликована: Фев. 1, 2025
Язык: Английский
Процитировано
0Drug Discovery Today, Год журнала: 2025, Номер unknown, С. 104352 - 104352
Опубликована: Апрель 1, 2025
Tauopathies, including Alzheimer's disease (AD), Pick's (PiD), progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD), are characterized by the misfolding pathological aggregation of tau protein, leading to neurodegeneration. Although pathogenesis these diseases is still a matter for debate, formation amyloid inclusions represents only histopathological hallmark available. Tau not same in terms structure morphology, different tauopathies polymorphs. Remarkably, selective detection polymorphs crucial differential diagnosis, monitoring evaluation potential harmfulness polymorphs, with significant impact on drug discovery. This review discusses recent advances development imaging probes designed forms associated specific tauopathies. We explore application compounds that can target characteristic AD, PiD, PSP CBD. In particular, we focus discussing probes' selectivity sensitivity distinguishing between tauopathy-associated preclinical settings. The progress weaknesses this field discussed, guide researchers identifying accurate potent diagnosis neurodegenerative diseases.
Язык: Английский
Процитировано
0Опубликована: Янв. 1, 2024
Язык: Английский
Процитировано
0